XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.87

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (12270)	11/19/1999 11:14:00 AM
From: aknahow	of 17367

Non novel patent! e-Coli is very common. Why should a patent about e-coli be any different? Besides XOMA probably can't explain how they will manage the situation of having a prospective product that is better than the existing product. Sort of means new clinical trials repeating old ones to prove it's better. So will XOMA eventually have to spend millions to get the peptide clinically tested against meningococemia to know its' own Neuprex off the shelves, if ever approved. Inquiring minds demand answers. Think Bob is also interested, or will be when he finishes his theory about what happens when three sailing ships leave from Spain. Hope I didn't give anything away.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next